Trikafta: A Novel Triple Therapy for Cystic Fibrosis
0048-0000-22-002-H01-P
Learning Objectives:
At the completion of this activity, the participant will be able to:
0048-0000-22-002-H01-P
Learning Objectives:
At the completion of this activity, the participant will be able to:
- Review the pathophysiology of cystic fibrosis and mechanism of action of current treatment options.
- Discuss the results of two phase 3 clinical trials that evaluated the safety and efficacy of elexacaftor, tezacaftor, and ivacaftor (Trikafta).
- Describe relevant clinical considerations when prescribing, dispensing, and monitoring therapy
trikafta_final_for_home_study_ce.pdf | |
File Size: | 2108 kb |
File Type: |